CONCORDBIO.NS
Key Ratios

Net Profit Margin: Making very high profit as compared to its revenue which generally means either business holds monopoly in the market or it is a high-margin business

Acid Test Ratio: It has very strong liquidity, which means it can can cover its liabilities without relying on inventory

Inventory Turnover: Very Slow Inventory movement or over stocking risk

Coverage Analysis: At a very strong financial position where company is easily able to pay its interest payments from its earnings (EBIT + Lease Payments)

Debt to Equity Ratio: Company has low debt when compared to its equity which means it is financially stable

P/E Ratio: Overvalued stock which means company is making very less revenue per share but stock price is very high which represent speculative stock

Performance Graph
Financial Ratios
Ratio Value
PE Ratio74.44
Net Profit Margin0.31
Acid Test Ratio4.84
Inventory Turnover1.16
Coverage Ratio69.08
Debt to Equity0.01
Key Ratios

Net Profit Margin: Making very high profit as compared to its revenue which generally means either business holds monopoly in the market or it is a high-margin business

Return on Assets: Very high efficiency of the assets which indicates assets are making high contribution to the revenue

Return on Equity: High income of the company when compared with its equity, which means efficient equity

Performance Graph
Profitability Ratios
Ratio Value
Net Profit Margin0.31
Return on Assets1.11
Return on Equity0.20
Performance Graph
Key Ratios

Acid Test Ratio: It has very strong liquidity, which means it can can cover its liabilities without relying on inventory

Current Ratio: It has excess cash even after covering its short-term liabilities, which also may indicates mismanagement os assets in some cases

Performance Graph
Liquidity Ratios
Ratio Value
Acid Test Ratio4.84
Current Ratio6.30
Performance Graph
Key Ratios

Inventory Turnover: Very Slow Inventory movement or over stocking risk

Performance Graph
Efficiency Ratios
Ratio Value
Inventory Turnover1.16
Performance Graph
Key Ratios

Coverage Analysis: At a very strong financial position where company is easily able to pay its interest payments from its earnings (EBIT + Lease Payments)

Performance Graph
Coverage Ratios
Ratio Value
Coverage Ratio69.08
Performance Graph
Key Ratios

Debt to Equity Ratio: Company has low debt when compared to its equity which means it is financially stable

Interest Coverage Ratio: Company is at low risk of getting default as it can easily cover its interest payments and strong financial health

Performance Graph
Solvency Ratios
Ratio Value
Debt to Equity Ratio0.01
Interest Coverage Ratio162.67
Performance Graph
Key Ratios

P/E Ratio: Overvalued stock which means company is making very less revenue per share but stock price is very high which represent speculative stock

Dividend Yield: NA

Performance Graph
Market Ratios
Ratio Value
P/E Ratio74.44
Gross Profit Margin0.76
Price to Book Ratio15.02
Dividend Yield0.00
Performance Graph

Balance Sheet Analysis of Concord Biotech Limited

The balance sheet in the financial statement of the company shows its financial position at a particular point in time.

It consists of the following:

  • Assets: Something that the company owns and that gives financial benefits over a period of time.
  • Liabilities: Something that a company owes and that has a financial burden on the company.
  • Equity: It is basically the owner’s share in the company.

The formula is:

Assets = Liabilities + Equity
đź“ŚAssets:
Asset
Value & Year
2024
2023
2022
Total Assets 17007085000 15139818000 13127950000
Total Non Current Assets 8044774000 7862817000 6801290000
Other Non Current Assets 79799000 - -
Non Current Prepaid Assets 111306000 169133000 284430000
Non Current Deferred Taxes Assets - - -
Financial Assets - - -
Investment In Financial Assets - 1246000 2560000
Held To Maturity Securities - - -
Available For Sale Securities 49695000 - -
Financial Assets Fair Value - 1246000 2560000
Long Term Equity Investment 20586000 - -
Investments In Associates At Cost - - -
Goodwill And Other Intangible Assets 3197000 1977000 35790000
Other Intangible Assets 3197000 1977000 35790000
Goodwill - - -
Net Ppe 7864785000 7654796000 6435550000
Accumulated Depreciation -2384583000 -1873062000 -1378490000
Gross Ppe 10249368000 9527858000 7814040000
Construction In Progress 2114824000 1726971000 741560000
Other Properties 519945000 493799000 432180000
Machinery Furniture Equipment 4459176000 4294524000 3853170000
Buildings And Improvements 2608312000 2465453000 2240020000
Land And Improvements 547111000 547111000 547110000
Properties - - -
Current Assets 8962311000 7277001000 6326660000
Other Current Assets 284933000 7116000 -
Hedging Assets Current 1212000 2500000 4980000
Assets Held For Sale Current - - -
Restricted Cash 56753000 93680000 10150000
Prepaid Assets 284552000 211954000 151980000
Inventory 2079538000 2123147000 1951170000
Other Inventories - - -
Finished Goods 165978000 148019000 221880000
Work In Process 1234802000 1131982000 901800000
Raw Materials 678758000 843146000 827490000
Other Receivables 188839000 383549000 268890000
Taxes Receivable - - -
Accounts Receivable 3496089000 2737576000 2321740000
Allowance For Doubtful Accounts Receivable -13907000 -8730000 -7810000
Gross Accounts Receivable 3509996000 2746306000 2329550000
Cash Cash Equivalents And Short Term Investments 2855328000 1811159000 1617750000
Other Short Term Investments 2703907000 1776167000 1611080000
Cash And Cash Equivalents 151421000 34992000 6670000
Cash Equivalents - - -
Cash Financial 151421000 34992000 6670000
đź“Ś Liabilities & Equity
Liability/Equity
Value & Year
2024
2023
2022
Net Debt - 277364000 599190000
Total Debt 97376000 315463000 624930000
Total Liabilities Net Minority Interest 1740630000 2239793000 2095720000
Total Non Current Liabilities Net Minority Interest 319076000 321350000 544040000
Other Non Current Liabilities - - -
Derivative Product Liabilities - - -
Non Current Pension And Other Postretirement Benefit Plans 19561000 22966000 18740000
Trade And Other Payables Non Current - - -
Non Current Deferred Revenue - - -
Non Current Deferred Taxes Liabilities 280645000 234390000 209710000
Long Term Debt And Capital Lease Obligation 18870000 63994000 315590000
Long Term Capital Lease Obligation 18870000 1638000 3110000
Long Term Debt - 62356000 312480000
Long Term Provisions 19561000 - -
Current Liabilities 1421554000 1918443000 1551680000
Other Current Liabilities 62675000 - -
Current Deferred Taxes Liabilities - - -
Current Debt And Capital Lease Obligation 78506000 251469000 309340000
Current Capital Lease Obligation 16208000 1469000 15960000
Current Debt 62298000 250000000 293380000
Pension And Other Post Retirement Benefit Plans Current - 274760000 17480000
Current Provisions 39019000 274757000 17480000
Payables 1266413000 1362539000 1068020000
Other Payable 267122000 334552000 236960000
Dividends Payable - - -
Total Tax Payable 54938000 89987000 -
Accounts Payable 944353000 938000000 831060000
Common Stock Equity 15266455000 12900025000 11032230000
Total Capitalization 15266455000 12962381000 11344710000
Total Equity Gross Minority Interest 15266455000 12900025000 11032230000
Minority Interest - - -
Stockholders Equity 15266455000 12900025000 11032230000
Other Equity Interest 15161839000 - -
Treasury Stock - - -
Retained Earnings 14049950000 11683520000 9815720000
Additional Paid In Capital 819710000 819710000 829220000
Capital Stock 104616000 104616000 95110000
Common Stock 104616000 104616000 95110000

Income statement interpretation for Concord Biotech Limited

The income statement in the financial statement of the company shows its company financial performance over a period in time.

It consists of the following:

  • Revenue: It is the total amount of money earned from the core business activity of the company.
  • Expenses: It is the total amount required for running the full functionality of the company.
  • Profit or loss:In very simple terms, when a company pays its expenses using its revenue, then what’s left is profit, and in case expenses are more when compared with revenue, then it is loss.
đź“ŚRevenue & Profitability
Revenue/Profitability
Value & Year
2024
2023
2022
Total Revenue 9980573000 8306322000 7084400000
Operating Revenue 9980573000 8306322000 7084400000
Cost Of Revenue 2416100000 1970667000 1779230000
Gross Profit 7564473000 6335655000 5305170000
Ebitda 4687084000 3805561000 2930520000
Ebit 4151169000 3265237000 2430020000
Operating Income 3862827000 3047457000 2361270000
Net Income 3081032000 2400857000 1749290000
Net Income From Continuing Operation Net Minority Interest 3081032000 2400857000 1749290000
Net Income From Continuing And Discontinued Operation 3081032000 2400857000 1749290000
Net Income Common Stockholders 3081032000 2400857000 1749290000
Net Income Including Noncontrolling Interests 3081032000 2400857000 1749290000
Net Income Discontinuous Operations - - -
Net Income Continuous Operations 3081032000 2400857000 1749290000
Normalized Income 2975150554 2369286104 1756323575
Normalized Ebitda 4544904000 3763127000 2940070000
Total Unusual Items 142180000 42434000 -9550000
Total Unusual Items Excluding Goodwill 142180000 42434000 -9550000
đź“ŚExpenses & Taxes
Expenses/Taxes
Value & Year
2024
2023
2022
Reconciled Depreciation 535915000 540324000 500500000
Reconciled Cost Of Revenue 2416100000 1970667000 1779230000
Total Expenses 6117746000 5258865000 4723130000
Operating Expense 3701646000 3288198000 2943900000
Other Operating Expenses 1669538000 1551033000 1264900000
Depreciation And Amortization In Income Statement 535915000 540324000 500500000
Amortization 3388000 33794000 33950000
Depreciation Income Statement 532527000 506530000 466550000
Selling General And Administration 442383000 342004000 320170000
Selling And Marketing Expense 331096000 236985000 214360000
General And Administrative Expense 111287000 105019000 105810000
Rent And Landing Fees 85581000 58980000 20000
Tax Provision 1044618000 819277000 625890000
Pretax Income 4125650000 3220134000 2375180000
Other Non Operating Income Expenses 23554000 15872000 9730000
Special Income Charges 1533000 5265000 -61850000
Other Special Charges -1533000 -5265000 -2690000
Write Off - - 64540000
Net Non Operating Interest Income Expense -1429000 -7437000 -13480000
Total Other Finance Cost 6321000 6742000 6510000
Interest Expense Non Operating 25519000 45103000 54840000
Interest Income Non Operating 30411000 44408000 47870000
đź“Ś Earnings Per Share
Earnings Per Share
Value & Year
2024
2023
2022
Diluted Eps 29.45 22.95 16.72
Basic Eps 29.45 22.95 16.72
Diluted Ni Avail To Com Stockholders 3081032000 2400857000 1749290000
Net Income From Continuing Operations 4125650000 3220134000 2375180000
Minority Interests - - -

Cash flow analysis for Concord Biotech Limited

The cashflow statement in the financial statement of the company shows how cash is moving in or moving out of the company over a period of time.

It consists of the following:

  • Operating activities: Cash flow from the core business operations.
  • Investing activities: Cashflow from investments made by the company.
  • Financing activities: These are cash from loans or by issuing shares or paying out dividends.
đź“ŚOperating Cash Flow
Operating Cash Flow
Value & Year
2024
2023
2022
Operating Cash Flow 2654671000 2460018000 2074750000
Changes In Cash 116429000 28323000 -44770000
Taxes Refund Paid -1033496000 -702766000 -607850000
Change In Working Capital -811798000 -522855000 -220530000
Change In Other Current Liabilities 61309000 -92053000 114060000
Change In Other Current Assets 3329000 -191310000 241700000
Change In Payable -112866000 98806000 365320000
Change In Inventory 43609000 -172273000 -415090000
Change In Receivables -786596000 -430971000 -527690000
Other Non Cash Items -15688000 -21947000 -22400000
Stock Based Compensation - - -
Provision And Write Off Of Assets 6313000 -16585000 19240000
Depreciation And Amortization 535915000 540324000 500500000
Amortization Cash Flow 3388000 33794000 33950000
Depreciation 532527000 506530000 466550000
đź“ŚInvesting Cash Flow
Investing Cash Flow
Value & Year
2024
2023
2022
Investing Cash Flow -1546093000 -1579501000 -1117880000
Net Other Investing Changes - - -
Interest Received Cfi 27728000 55849000 41390000
Dividends Received Cfi - - -
Net Investment Purchase And Sale -718687000 -184755000 395220000
Sale Of Investment 7662313000 6246237000 5614360000
Purchase Of Investment -8381000000 -6430992000 -5219140000
Net Business Purchase And Sale - - -
Sale Of Business - - -
Purchase Of Business - - -
Net Ppe Purchase And Sale -855134000 -1450595000 -1554490000
Sale Of Ppe 1751000 253000 560000
Purchase Of Ppe -856885000 -1450848000 -1555050000
Net Intangibles Purchase And Sale - - -
Purchase Of Intangibles - - -
đź“Ś Financing Cash Flow
Financing Cash Flow
Value & Year
2024
2023
2022
Financing Cash Flow -992149000 -852194000 -1001640000
Net Other Financing Charges 13912000 32356000 30890000
Interest Paid Cff -26496000 -39582000 -53150000
Cash Dividends Paid -714529000 -535635000 -705210000
Common Stock Dividend Paid -714529000 -535635000 -
Net Common Stock Issuance - - -
Common Stock Payments - - -
Common Stock Issuance - - -
Repurchase Of Capital Stock - - -
Repayment Of Debt -250058000 -250000000 -250020000
Issuance Of Debt - - -
Issuance Of Capital Stock - - -
Net Issuance Payments Of Debt -250058000 -293372000 -257630000
Net Short Term Debt Issuance - -43372000 -7610000
Short Term Debt Issuance - - -
Net Long Term Debt Issuance -250058000 -250000000 -250020000
Long Term Debt Payments -250058000 -250000000 -250020000
Long Term Debt Issuance - - -
Net Preferred Stock Issuance - - -
Preferred Stock Payments - - -

Summary

Fundamental Overview of CONCORDBIO.NS (Concord Biotech Limited)

Above is the summary for fundamental analysis of Concord Biotech Limited , whose ticker name is CONCORDBIO.NS and belongs to sector Healthcare, and it is listed in NSE (National Stock Exchange).

The Concord Biotech Limited which is listed in NSE (National Stock Exchange) has a PE ratio of 74.44, CONCORDBIO.NS has a net profit margin of 0.31, the acid test ratio for CONCORDBIO.NS is 4.84, CONCORDBIO.NS has an inventory turnover of 1.16, and CONCORDBIO.NS has debt-to-equity ratio of 0.01.

The CONCORDBIO.NS whose company name is Concord Biotech Limited has made profit/loss of 7564473000 with total revenue of 9980573000, CONCORDBIO.NS has assets worth of 17007085000.

1. What is fundamental analysis?

Fundamental analysis is looking into a company’s real business performance by analyzing financial statements, earning reports, and key valuation ratios.

Basically, fundamental analysis involves examining a company’s revenue, profits, losses, debts, assets, liabilities, and ratios calculated using these values to determine long-term investment strategies.

Fundamental analysis may not work for short-term trading of stock; it is usually incorporated by long-term investors.

2. Importance of Fundamental Analysis

Imagine you are locking a good amount of funds into an unknown company for many years. Sounds stupid, right?

This is where fundamental analysis comes into the picture, which turns an unknown enemy into a known friend.

As fundamental analysis involves calculating how a company is actually performing, the real revenue, profits, assets, liabilities, debts, and more. This helps investors to determine what the actual current financial condition of the company is, how much the company’s stock price is justified when compared to earnings (Corporate earnings reports India) that it is making through business, what the probability is that the company will go bankrupt in the future, how much growth the company has shown in the past, and other financial ratios.

All these calculations and analyses determine the financial health of the company, historical business growth, company’s efficiency, and its stock price compared with real earnings (Corporate earnings reports India), which helps traders to make investment decisions for long-term investment strategies.

2. How to Use Our Tool

  • Search for the stock that you want to analyze in the search bar by typing the name of the company or ticker.
  • Once you land on the Stock Analytics Page, click on “Fundamental Analysis”; this will take you to the fundamental analysis page.
  • Apply Filter
  • On the “Fundamental Analysis” page, the first tab is for “Summary and Ratio,” where in the top section you can find the overall summary of the stock’s fundamental analysis, where on the leftmost side it has a textual summary, then in the middle a gauge chart that represents overall financial health, and then a list of important ratios.
  • Apply Filter
  • Then in the same “Summary and Ratio” tab, we have included a detailed analysis of stock in various aspects, which includes “Profitability Analysis,” “Liquidity Analysis,” “Efficiency Analysis,” “Coverage Analysis,” Solvency Analysis,” and “Market Analysis,” which divide the stock’s fundamentals into the above aspects and analyze each in the same format as for overall analysis, where the leftmost side has a textual summary, then in the middle a gauge chart that represents overall analysis of the particular section, and then a list of important ratios. Required for the particular analysis.
  • Apply Filter